|
IGBA launches a Biosimilar Medicines Information Campaign |
Medicines for Europe |
Thu, 02/01/2018 |
Health & Consumers |
|
IGBA congratulates the Australian Government for maintaining their Biologics Naming Convention and for strengthening pharmacovigilance |
Medicines for Europe |
Mon, 01/29/2018 |
Health & Consumers |
|
2018 – A year of unprecedented challenges and opportunities for pharmaceutical regulatory systems |
Medicines for Europe |
Thu, 01/25/2018 |
Health & Consumers |
|
Vigilance saves lives! More focus needed on sustainability and patient engagement |
Medicines for Europe |
Wed, 01/24/2018 |
Health & Consumers |
|
Report shows life sciences industry alliance is taking action to curb antimicrobial resistance, with more to come |
Medicines for Europe |
Thu, 01/18/2018 |
Health & Consumers, InfoSociety |
|
Brexit - Life Science Industry Joint Position Paper |
Medicines for Europe |
Thu, 12/14/2017 |
Health & Consumers, UK in Europe |
|
European Commission launches: “What I need to know about Biosimilar Medicines - Information for patients”, in 23 EU languages |
Medicines for Europe |
Wed, 11/29/2017 |
Health & Consumers |
|
Europe’s life science industry urges the UK and EU27 to safeguard patients’ access to medicines with a clear transition period and a future cooperation agreement after Brexit |
Medicines for Europe |
Tue, 11/28/2017 |
Health & Consumers, UK in Europe |
|
Medicines for Europe calls for greater cooperation on value added medicines to improve patient-centric innovation |
Medicines for Europe |
Wed, 11/22/2017 |
Health & Consumers |
|
Commission sponsored study shows Supplementary Protection Certificate (SPC) Manufacturing Waiver will create Jobs, strengthen the pharmaceutical sector and reduce medicine costs |
Medicines for Europe |
Wed, 10/18/2017 |
Health & Consumers |
|
Medicines for Europe announces new President, launches Access to Medicines campaign |
Medicines for Europe |
Tue, 10/10/2017 |
Health & Consumers |
|
Medicines for Europe to join the ISPOR Issue Panel on value added medicines |
Medicines for Europe |
Thu, 10/05/2017 |
Health & Consumers |
|
Addressing medicine shortages in Europe: Competition is crucial for patient access |
Medicines for Europe |
Fri, 09/29/2017 |
Health & Consumers, Competition |
|
2017 Biosimilar Medicines Policy Overview: better access is crucial; tailored solutions essential for EU governments |
Medicines for Europe |
Tue, 09/12/2017 |
Health & Consumers |
|
Oncology, the new era for biosimilar medicines |
Medicines for Europe |
Fri, 09/08/2017 |
Health & Consumers |
|
Value Added Medicines: Time to adjust the HTA Decision Frameworks for more patient-centric innovation |
Medicines for Europe |
Tue, 09/05/2017 |
Health & Consumers |
|
Latest Data Shows the Need to Promote Biosimilar and Value Added Medicines for Better Health |
Medicines for Europe |
Fri, 06/16/2017 |
Health & Consumers |
|
62% of Medicines Dispensed in Europe are Generic, according to IMS New Data |
Medicines for Europe |
Thu, 06/15/2017 |
Health & Consumers |
|
EU Semester Country Specific Recommendations: More Efficient Medicine Policies Needed for Patient Access |
Medicines for Europe |
Tue, 05/23/2017 |
Health & Consumers |
|
Biosimilar Medicines Opportunity: Dramatic Increase in Patient Access across Europe |
Medicines for Europe |
Tue, 05/09/2017 |
Health & Consumers |
|
Medicines for Europe can contribute much more to improve healthcare sustainability than described in the OECD “Health at a Glance 2016” report |
Medicines for Europe |
Thu, 11/24/2016 |
Health & Consumers |
|
Fulfilling the Biosimilar Promise: Report Highlights Key Principles in Support of a Sustainable Market |
Medicines for Europe |
Mon, 09/19/2016 |
Health & Consumers |
